Summary.-l. Successive sampling of ovarian cancers during cytostatic treatment showed several cases of notable changes in their ploidy distribution and one change in modal chromosome number, indicating selection of a resistant tumour-cell population. 2. Studies of cell suspensions from human tumour specimens incubated with [3H] -TdR after exposure in vitro to various cytostatic agents have shown variation in labelling between different parts of the same tumour, as well as between the primary tumour and its metastases or ascitic tumour-cell population, which may be accounted for by variation in sensitivity of the tumour-cell population. 3. Studies of nuclear morphology in 20 endometrial cancers before and after progesterone therapy demonstrate considerable variation in the proportion of cells undergoing secretory conversion within the same tumour, indicating primary heterogeneity of the tumour-cell population in response to progesterone.
PERSISTENCE and early recurrence of human tumours after cytostatic or hormonal treatment starts from surviving cells. Such cells may be less sensitive due to natural primary resistance to the treatment. This postulates that the tumourcell population is heterogeneous for sensitivity to various cytostatic drugs or hormones.
Cytogenetic and cytochemical studies have demonstrated that some experimental as well as human tumours are composed of more than one cell clone, which often differ significantly in their biological characteristics (Bishun et al., in different sensitivities to various cytostatic drugs, both in animal and human tumour-cell lines (Hakansson & Trope, 1974; Trope & Hakansson, 1974; Trope et al., 1975; Whisson & Siracky, 1969) .
There is still the problem of estimating or characterizing the type and degree of cellular heterogeneity of human tumours in respect of their sensitivity to various therapeutic agents, at the cellular level and in vtvo.
In the present investigations we have attempted clinical interpretation of the problem of cellular heterogeneity in different types and sites of human tumours. Tissue samples were obtained at the diagnostic curettage (A sample). All patients were then submitted to progesterone therapy (DEPO Provera, Upjohn S.A., Puurs, Belgium) i.m. on consecutive days to a total amount of 600 mg. On the 8th-lOth day after progesterone therapy, several tissue samples (B sample) were obtained, either from curettage before intracavitary radium treatment, or at hysterectomy. All tissue specimens were fixed in methanol/formalin/acetic-acid mixture for 24 h, embedded in paraffin and 4 ,um histological section were stained with haematoxylin and eosin. In each specimen (A or B) 150-200 tumour-cell nuclei were studied at random for measurement of the long and slhort axes, the ratio of the 2 axes being expressed as the "elongation". Secretory conversion of the endometrial cell population is morphologically expressed by shortening of the long axis of the nuclei, thus decreasing the elongation (Epifanova, 1971) .
MATERIALS AND METHODS
In all these specimens some aspects of cell kinetics were also studied using double labelling wvith 3H-TdR-14C-TdR, the results of which are published separately (Siracky et al., 1978) .
RESULTS AND DISCUSSION

Ploidy
All the cases in our series were characterized before treatment by a wide range of ploidy, with modal chromosome numbers in the diploid or hyperdiploid range, which is characteristic of ascites tumour cell populations in ovarian cancer (Atkin, 1976; Koller, 1972) .
"Number of mitoses studied" in Table I refers to samples studied before, during and after cytostatic treatment in sequence. Some of the cases are represented by only 2 samples (before and after treatment) due to inhibition of the ascites proliferation. "Modal chromosome number" refers to the pretreatment sample, and apart from case No. 11 (Fig. 2) no changes in modal chromosome number during cytostatic treatment were detected. In several of these cases, however, distinct changes in ploidy distribution (Koller, 1972) which is also to be expected as the result of damage to the mitotic process of cells by alkylating agents (Bishun, 1971; Nasjleti & Spencer, 1967 Tables II, III and IV: ALK-0-2 mg/ml FF-2-0 mg/ml FU-0 5 mg/ml MTX-0.05 mg/ml OXAUR-0.01 mg/ml TS-0-1 mg/ml VINBL-0-1 mg/ml VINCR-0 1 mg/ml N clear morphology Clinical experience has shown that endometrial cancers are hormone (progesterone) responsive in a considerable percentage of cases (Kelley & Baker, 1965; Smith et al., 1966) . Several studies have also demonstrated secretory conversion, mostly in highly differentiated cancers, manifesting itself by characteristic changes in nuclear morphology as a result of progesterone treatment (Hustin, 1976; Martinez-Manaton et al., 1975) . Secretory conversion implies loss of proliferative Table V) . A=before and B = after treatment.
capacity and might be a prelethal stage (Epifanova, 1971) . Most of the highly differentiated cancers in our series exhibited significant responses to progesterone, expressed as rising values of potential doubling time in post-treatment specimens (Siracky et al., 1978) as well as showing secretory conversion of a significant fraction of the tumour-cell population (Table V, Fig. 3 ). In highly differentiated cancers of our series the ratio of long-short axis of nuclei changed from 1*74 + 052 before to 1-35 + 0-41 after progesterone treatment. The mean length of the long axis was 10X38 + 2X34 ,m before and 8X69 + 2X03 ,m after treatment.
Examples of the changes in nuclear morphology after progesterone treatment are shown in Figs 3 and 4. In the group of moderately and poorly differentiated cancers, in spite of nearly unchanged values both in proliferation kinetics and nuclear morphology after progesterone treatment, a distinct fraction of the tumour-cell population undergoing secretory conversion could be detected by plotting the nuclear morphology parameters in nomograms (Fig. 4) which clearly demonstrated differences in response to progesterone treatment within the cell population of a single tumour. It appears, however, that recognition of 2 different types of cell population, as seen in Fig. 4B , would be possible only in tumours with about equal amounts of both cell types.
